Following a similar decision in case the trade group Outsourcing Facilities Association brought against FDA over its decision ...

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list.

Compared with semaglutide and insulin, tirzepatide was associated with improved glycemic control and weight loss outcomes among patients with type 2 diabetes. Tirzepatide is associated with longer ...

Sharp increases were seen in dispensations of tirzepatide (0.0 to 40.6%) and semaglutide (2.4 mg; 0.0 to 32.2%) among adults without diabetes but prescribed WLMs; the most frequently dispensed WLM ...